HER2-positive (HER2+) breast cancer treatments come with a range of unpleasant side effects. However, there are strategies ...

引言CAR-T（嵌合抗原受体T细胞）疗法在血液系统恶性肿瘤的治疗中取得了突破性进展。然而，由于实体瘤的肿瘤微环境（TME）高度免疫抑制、肿瘤抗原表达的异质性及T细胞渗透能力受限，CAR-T在实体瘤治疗中面临显著挑战。为克服这些问题，2月7日Natur ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

Medically reviewed by Archana Sharma, DO Eating well can help support your immune system and maintain strength and energy if ...

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

For those whose tumors also demonstrate HER2 amplification (extra copies of the HER2 gene), this therapy may be less effective. In the SWOG S1613 clinical trial comparing this standard therapy to ...

OS Therapies还宣布从Ayala战略性收购临床和知识产权资产，包括两个用于肺癌和前列腺癌的李斯特菌基免疫疗法候选药物。这次收购不仅扩大了公司的临床产品组合，还显著降低了预期的现金里程碑付款和特许权使用费率，提高了OST-HER2的利润率。

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...

During a Case-Based Roundtable event, Laura Huppert, MD, discussed data and considerations around using T-DXd in breast ...